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Abstract: Foot-and-mouth disease remains one of the world’s most economically important 
diseases of livestock. It is caused by foot-and-mouth disease virus, a member of the picorna-
virus family. The virus replicates very rapidly and can be efficiently transmitted between hosts 
by a variety of routes. The disease has been effectively controlled in some parts of the world 
but remains endemic in many others, thus there is a constant risk of introduction of the disease 
into areas that are normally free of foot-and-mouth disease with potentially huge economic 
consequences. To reduce the need for large-scale culling of infected, and potentially infected, 
animals there has been significant effort to develop new vaccines against this disease which 
avoid some, or all, of the deficiencies of current vaccines. A major focus has been on the use of 
systems that express the structural proteins of the virus that self-assemble to generate “empty 
capsid” particles which share many features with the intact virus but lack the ribonucleic acid 
genome and are therefore non-infectious. Such particles can be “designed” to improve their 
stability or modify their antigenicity and can be produced without “high containment”  facilities. 
The development and use of such improved vaccines should assist in the global efforts to control 
this important disease.
Keywords: picornavirus, diagnostic assays, virus structure, infection, immune responses
Introduction
Foot-and-mouth disease (FMD) is one of the most-feared diseases of farmed animals. 
It affects over 100 countries globally and many of the countries in Africa, the Middle 
East, and southern Asia experience FMD as an endemic disease. The disease continues 
to cause huge economic losses (estimated at around US$10,000,000,000 per year) 
on a global basis1 and can cause losses of this magnitude in a single country when 
incursions occur into a state that is normally FMD free (eg, in the UK in 2001). The 
latter outbreak affected over 2,000 premises and resulted in the slaughter of several 
million animals. Many of these animals were not actually infected but were culled to 
prevent further spread of the disease or for welfare reasons. The mass culling of ani-
mals is clearly undesirable and has generated renewed interest in the development of 
efficient and safe vaccines that can be used to assist in the control of FMD outbreaks. 
The economic impact of FMD means that there are large barriers to prevent trade in 
animals, and their products, from areas of the world with FMD.
FMD is caused by infection with foot-and-mouth disease virus (FMDV); this is 
the prototypic member of the Aphthovirus genus within the family Picornaviridae. 
As with all picornaviruses, FMDV has a positive-sense, single-stranded, ribonucleic 
acid (RNA) genome (Figure 1). Within the virus particle, a single copy of the genome 
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Figure 1 Structure of the FMDV genome.
Notes: The FMDV genome includes a single large open reading frame encoding a polyprotein. This coding region is flanked by the 5′-untranslated region (UTR) (ca 1,300 
nt) and a 3′-UTR (ca 90 nt). The RNA includes a polyA tail at the 3′ terminus. The 5′ UTR includes a poly(C) tract, of unknown function, and the iReS which directs the 
initiation of protein synthesis on the viral RNA. Two initiation codons are used (separated by 84 nt) to produce two forms of the first part of the polyprotein (the leader 
[L] protein), termed Lab and Lb.
Abbreviations: FMDV, foot-and-mouth disease virus; RNA, ribonucleic acid; iReS, internal ribosome entry site; VPg, viral protein-genome linked; nt, nucleotides; 
ca, circa.
is enclosed within a roughly spherical protein shell (capsid) 
which is about 30 nm in diameter. The capsid serves to pro-
tect the genome while the virus is outside of cells and also 
allows it to bind and subsequently gain entry to cells through 
interaction with specific cell-surface receptors (eg, certain 
integrins). Interaction of antibodies against the surface of the 
virus capsid is considered to be the major mechanism for neu-
tralizing FMDV infectivity. Thus vaccines to combat FMDV 
infection have been developed to generate antibodies against 
the capsid proteins. Current vaccines rely on the production of 
huge quantities of infectious FMDV, generally in large scale 
tissue culture systems, which is then chemically inactivated 
prior to inoculation into animals with an adjuvant.
The virus capsid is composed of 60 copies of four distinct 
proteins, termed VP1, VP2, VP3, and VP4 (see Figure 2), 
these are the structural proteins (SPs). The virus also produces 
eleven other different mature proteins (plus precursors) which 
are involved in the replication of the virus and/or combating 
host defense systems (see Characteristics of FMDV).
There are seven different serotypes of FMDV, namely O, 
A, C, Asia-1, Southern African Territories (SAT) 1, SAT 2, 
and SAT 3. There is no apparent cross protection between 
the serotypes, so animals that have been infected (or vac-
cinated) with one serotype of virus are not protected against 
other serotypes. Indeed, even within a single serotype there is 
considerable antigenic heterogeneity and thus vaccine match-
ing studies have been undertaken to identify the efficacy of 
particular vaccine strains in generating antibodies that block 
infectivity of new outbreak strains.
The immunity conferred by vaccination against FMDV 
is quite short-lived;2 it is commonly recommended, in areas 
with endemic disease, to revaccinate animals twice per year. 
In recent years, it has become usual to purify vaccine prepara-
tions to separate the virus particles (including the SPs) away 
from the non-structural proteins (NSPs). This can enable 
differentiation between animals that have been vaccinated 
(which will only have antibodies against the SPs) from those 
that have been infected (which can have antibodies against 
all the virus encoded proteins). However, vaccinated animals 
can still become sub-clinically infected which results in a 
low level immune response against the NSPs but a boost to 
the antibody response against the SPs.3 Hence, this differen-
tiation between infected and vaccinated animals (DIVA) is 
not perfect, especially since multiple rounds of vaccination, 
even with purified vaccines, can result in the induction of 
antibodies against NSPs which will be present at a low level 
in these vaccine preparations.
FMDV vaccine is heat labile and hence the maintenance 
of a “cold chain” for the vaccine before its administration is 
essential. A manufacturer may produce a good vaccine but 
if it is stored poorly then it may not function well when it is 
used and thus there is a need to determine vaccine quality, 
at the point of production, and also efficacy during vaccina-
tion campaigns.4
The text above indicates that there are a number of limita-
tions and problems associated with current FMDV vaccines 
(eg, lack of cross protection, short duration of immunity, labil-
ity, requirement for high containment facilities to produce it) 
and thus there is interest in developing improved vaccines 
which address at least some of these shortcomings. It may 
well be that there will not be a single solution to these different 
issues and indeed the most important features of a vaccine 
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may depend on their planned use. For example, in a country 
that is normally disease-free, the highest priority may be to 
use a vaccine which induces rapid protection against disease 
caused by the single type of virus that has been  introduced. 
In contrast, in endemic areas (with poor infrastructure) which 
may have multiple serotypes of FMDV in circulation concur-
rently, it may be best to have a stable vaccine (without need 
for a cold-chain) which induces broad protection, ideally 
against multiple serotypes, if this is achievable.
Characteristics of FMD
FMD is highly contagious and affects cloven-hoofed farmed 
animals including cattle, pigs, sheep, and goats. It can also 
affect a large number (circa 70) of different wildlife species 
including, notably, the African buffalo (Syncerus caffer). 
Severity of clinical disease varies between the common 
domestic species, with pigs developing severe clinical illness, 
followed by cattle showing clear but less severe clinical signs, 
whilst the clinical course of the infection in sheep and goats 
may be very mild.5
The different serotypes of FMDV cause clinically 
indistinguishable signs of disease. The initial FMDV rep-
lication within infected animals is thought to occur within 
the epithelia of the pharyngeal mucosa.6,7 From here, the 
virus spreads through the lymphatic and vascular system to 
peripheral sites of secondary replication, characterized by the 
presence of stratified, cornified, squamous epithelia, such as 
the coronary bands and oral cavity. Infected animals develop 
transient viremia lasting for 2–3 days, which is effectively 
counteracted by the development of circulating anti-FMDV 
antibodies. The clinical disease follows a rapid time course 
and typically includes a sudden rise in body temperature 
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Figure 2 Schematic diagram showing the production and assembly of FMDV capsid proteins.
Notes: The virus encoded polyprotein is cleaved, mainly by the virus encoded 3C protease (3Cpro) but the Leader protein (L) cleaves the L/VP0 junction. The capsid protein 
precursor (P1-2A) is processed to VP0, VP3, VP1, and 2A (a short peptide) and these proteins can self-assemble to form empty capsid particles. During virus infection, 
production of mature virus particles includes the encapsidation of the viral RNA genome and during this process cleavage of VP0 to VP4 and VP2 occurs. Only VP1, VP2, and 
VP3 are exposed on the surface of the virus particle, VP4 is entirely internal. The RNA genome (indicated as an orange line) within complete virus particles is absent from 
empty capsid particles which are therefore non-infectious.
Abbreviations: FMDV, foot-and-mouth disease virus; RNA, ribonucleic acid.
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and the development of vesicular lesions at peripheral areas 
of viral replication. Affected animals may display varying 
degrees of salivation, loss of appetite, and lameness according 
to the severity of lesions. The clinical course of the infection 
usually subsides within 7–14 days. However, many infected 
cattle (approximately 50%) may become FMDV “carriers”; 
these are defined as animals with asymptomatic, intermit-
tent, presence of infectious virus in the oropharyngeal fluid 
for more than 28 days after infection.8 Development of the 
“carrier” state is apparently unaffected by the presence of 
neutralizing antibodies in the circulation. Thus, both animals 
that are immunologically naïve at the time of exposure to 
FMDV, as well as those with circulating antibodies due to 
vaccination or previous exposure to the virus can become 
FMDV “carriers”. The duration of the “carrier” state var-
ies between species, with the longest duration recorded in 
African buffalo (5 years) followed by cattle (2 years) and 
sheep (9 months).9,10 It is generally considered that pigs do 
not become “carriers”5 but they may retain viral RNA for 
an extensive period (see below).11 Since “carrier animals” 
are a potential source of infectious virus, their presence is 
considered unacceptable in areas free of FMD, however it 
has proven very difficult to demonstrate transmission of virus 
from carriers to naïve animals.5,12
Transmission of the virus can occur by a variety of dif-
ferent routes. Cattle can easily be infected by airborne virus 
whereas pigs need close contact with other infected animals 
since a gap of .70 cm is sufficient to block transmission 
of the virus from one pig to another.13 In some instances, it 
appears that long distance (.100 km) transmission of the 
virus through the air to cattle has occurred; this has mainly 
been over water and may require specific weather conditions. 
During outbreaks, disease spread normally occurs on a rela-
tively local basis (within a few km) but clearly transporta-
tion of infected animals can seed new outbreaks in diverse 
 locations. Once infected, pigs exhale large quantities of virus 
and hence a common route of transmission is from infected 
pigs to cattle located downwind of these animals.5
Characteristics of FMDV
The FMDV life cycle is very short, indeed a single cell can 
be infected and produce .105 new virus particles in about 
5 hours. The replication of the virus is carried out entirely 
within the cytoplasm of the cell and the viral RNA alone is 
sufficient to initiate an infection if it is delivered to the cyto-
plasm of cells.14 The FMDV genome is about 8,400 nt long 
and encodes a large polyprotein from within a single open 
reading frame of about 7,000 nt (see Figure1). The uncapped 
viral RNA includes a very long (ca 1,300 nt) 5′-untranslated 
region (UTR) and a short 3′-UTR (ca 90 nt) plus a poly(A) 
tail.15 The 5′-UTR contains a poly(C) tract, multiple pseudo-
knots (of unknown function), a cis-acting replication element 
(cre) (also referred to as a 3B-uridylylation site [bus])16 and an 
internal ribosome entry site (IRES) which directs the initia-
tion of protein synthesis on the viral RNA.15 The full-length 
“polyprotein” is never observed since processing, largely by 
virus-encoded proteases, commences during the process of 
protein synthesis. In total 15 different mature polypeptides are 
made plus a variety of different precursor proteins some of 
which have functional significance with unique functions.
The initiation of protein synthesis on the FMDV RNA, 
directed by the IRES, occurs at two different sites separated, 
usually, by 84 nt.15 This results in the production of two dif-
ferent forms of the Leader (L) protein, the first component 
of the polyprotein, and these are termed Lab and Lb. It has 
been shown that these two forms of the L protein share the 
known major functions of this papain-like cysteine protease.17 
They can both cleave the L/P1 junction, in trans and probably 
in cis as well. They can also both induce the cleavage of the 
eukaryotic initiation factor 4G (eIF4G) which is an essential 
component of the cap-binding complex. Cleavage of eIF4G 
results in separation of the N-terminal domain (that binds 
to the cap-binding protein eIF4E) away from the rest of the 
complex. The modified complex is still able to support cap-
independent translation initiation on the FMDV IRES15 and 
so FMDV protein synthesis can occur but does not support 
cap-dependent protein synthesis, hence translation of cellular 
messenger (m)RNAs is efficiently blocked.
The FMDV SP precursor, P1-2A, has a  myristoylation 
signal sequence (GXXXS/T)18 at its N-terminus and hence 
the N-terminal glycine residue (generated through the action 
of the L protease as indicated above) becomes modified by 
the addition of a myristate group through the action of the 
cellular modification system (see Figure 3). The presence 
of the myristate group appears important for the  assembly/
or stability of the capsid of FMDV and certain other 
picornaviruses.19,20 The break at the junction between P1-2A 
and 2B is unusual; it requires the 2A peptide but this short, 
highly conserved, peptide lacks protease motifs and only 
functions to interrupt the formation of the polypeptide chain 
during polypeptide synthesis. It has been suggested that it 
induces “ribosomal skipping” at the NPG/P junction so that 
no peptide bond is actually made.21 Processing of P1-2A pre-
cursor to produce VP0, VP3, VP1, and 2A is achieved by the 
3C protease (3Cpro), and the final cleavage of VP0 to VP2 and 
VP4 occurs in the context of the assembled capsid. It used to 
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The 3A protein may serve to deliver the VPg peptides to 
the RNA replication machinery.32 Variants of FMDV with 
deletions within the 3A protein have been identified; these 
are associated with more restricted host range of the virus 
including attenuation in cattle.34 As indicated above, the 3C 
protein is a chymotrypsin-like protease and is responsible for 
most of the proteolytic cleavages within the virus encoded 
polyprotein (see Figure 2). In contrast to poliovirus (PV) 
and other enteroviruses, which require 3CD as the active 
protease for P1 processing, the FMDV 3Cpro is sufficient for 
all processing events within P1-2A. The 3Cpro also has an 
RNA-binding region32 and this may underlie its involvement 
(either alone or as part of the 3CD precursor) in the process 
of VPg uridylylation.32 The 3D protein is the RNA dependent 
RNA polymerase (3Dpol) and hence is critical for the process 
of RNA replication; this involves the production of a nega-
tive strand RNA template and then many more copies of the 
positive strand genome.
Diagnostics for FMDV; current  
tests and detection methods
Suspected cases of FMD are identified based on clinical 
signs, including fever, excessive salivation, presence of 
vesicles on the oral mucosa, on the nose plus the inter-digital 
spaces and coronary bands on the feet. However, the clini-
cal signs can be confused with other diseases (eg, vesicular 
stomatitis and swine vesicular disease) and thus a laboratory 
based diagnosis is required. The first priority is the specific 
detection of FMDV but it is also important to identify the 
serotype of virus involved in outbreaks (if vaccination is 
considered) and sequence analysis can be used to identify 
the potential source of the introduced virus.
Detection of FMDV RNA
The currently favored technique for the detection of FMDV 
is the use of reverse transcription quantitative polymerase 
chain reaction (RT-qPCR) assays; these are rapid, sensitive, 
and specific. Currently, two different RT-qPCR assays which 
recognize highly conserved parts of the genome are in com-
mon use, one targeting part of the IRES within the 5′ UTR35 
and the second targeting a region within the 3Dpol coding 
sequence.36 These assays can be performed using robotic 
extraction of RNA and thus can achieve relatively high 
throughput, especially using one-step RT-qPCR procedures.37 
Thus the assays are suitable for the diagnosis of a primary 
index case and for use in an ongoing outbreak. However, these 
assays are not designed to discriminate between serotypes 
of FMDV and each of the assays can fail to detect particular 
..KAKGAGQSS...
GAGQSS.....KAK
Cellular N-myristoyl transferase + myristate
myr-GAGQSS...
L VP0
VP0L
Figure 3 Myristoylation of FMDV capsid proteins by host cell systems.
Notes: Cleavage of the L/VP0 junction by the Leader (L) protease (indicated by 
arrow) generates an N-terminal glycine (G) residue on VP0 within the consensus 
motif (GXXXS/T) that is recognized by the cellular myristoylation system. Addition 
of the myristate (myr) moiety (indicated by ◄) is required for the formation of 
empty capsid particles and virions.
Abbreviation: FMDV, foot-and-mouth disease virus.
be thought that this cleavage was dependent on packaging of 
the genome, however, it has become apparent that it occurs 
within assembled “empty” capsid particles (lacking the RNA 
genome) too22–24 but the mechanism is not known.
The P2 and P3 regions of the polyprotein include the 
NSPs. The functions of the P2 region (which is processed by 
3Cpro to produce 2B and 2C) are not very well understood. It 
has been shown that 2BC or 2B together with 2C can inhibit 
trafficking of proteins to the cell surface,25,26 this may have 
an adverse effect on the presentation of viral proteins to the 
host immune system, thus protecting the virus from immune 
defenses. The 2C protein is also implicated in viral RNA 
replication since it is the site of action of guanidine which 
can block this process. Mutants of the virus which become 
resistant to this inhibitor have mutations within the 2C cod-
ing region.27–29 Recent studies have shown that the FMDV 
2C protein is a member of the AAA+ family of proteins and 
forms a hexameric structure.30
The P3 region is processed to 3A, three different forms 
of 3B (3B
1
, 3B
2
 and 3B
3
 which are often called VPgs [viral 
protein-genome linked]), 3C and 3D. The 3B peptides 
(23 or 24 amino acids each) are modified in an unusual 
reaction involving the covalent linkage of uridyl residues to 
a conserved tyrosine (Y) residue within each VPg.31,32 The 
VPgpUpU then acts as a primer for the initiation of RNA 
synthesis and thus all picornavirus RNAs have a 5′-terminus 
comprising VPg-UU…. FMDV is unique in having three 
 different versions of the VPg peptide and each is functional.33 
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FMDVs due to the presence of nucleotide mismatches within 
the region targeted by the primers and probes. Thus, no single 
stand-alone assay is capable of detecting FMDV with 100% 
certainty. There has been recent work to develop RT-qPCR 
assays for serotyping of FMDV,38 however due to the diversity 
of the viruses in different areas of the world it is likely that 
such assays will have to be tailored to specific global regions. 
Alternative nucleic acid amplification methods (eg, LAMP 
[loop-mediated isothermal amplification]) have also been 
described for the detection of FMDV RNA39 which may be 
applicable in certain settings.
Virus isolation
Until the advent of RT-qPCR assays, the preferred technique 
for the detection of FMDV was the use of virus isolation fol-
lowed by its characterization. Primary cell cultures  (especially 
bovine thyroid cells) or certain cell lines (eg, BHK or IBRS2) 
are suitable for isolation of FMDV. Up to 4 days (using two 
passages of up to 2 days) may be required to demonstrate the 
presence of virus, especially when the initial levels of virus 
are low, and therefore it also takes 4 days to be confident that 
no virus is present.
FMDV antigen detection
Roeder and Le Blanc-Smith40 established assays for the 
detection of FMDV antigen using high titer anti-FMDV 
antisera raised in rabbits and guinea pigs for antigen cap-
ture and detection, respectively. The assays are serotype 
specific and quick, thus they are frequently used for the 
diagnosis of FMD and for virus typing. However, the 
enzyme-linked immunosorbent assay (ELISA) is not 
very sensitive and only gives positive results with about 
70%–80% of epithelial suspensions that contain the virus. 
Thus the virus may have to be propagated in cell culture 
(as described above) and subsequently tested in the ELISA 
to detect the virus and ascertain the serotype; clearly this 
significantly lengthens the procedure. Variants of this 
procedure also exist; for example, monoclonal antibody 
(Mab)-based ELISAs have been developed for detection 
and typing of FMDV41 and a sandwich ELISA using recom-
binant integrin αvβ6 (a cellular receptor for FMDV) for 
virus capture and serotype-specific monoclonal antibodies 
as detecting reagents was reported.42 These integrin/Mab 
ELISAs recognized FMDVs of broad antigenic diversity 
from all seven serotypes.
A Mab-based chromatographic strip test for FMDV 
detection was developed43 as a pen-side test. This system 
can be as sensitive as the conventional antigen ELISA for 
the detection of FMDV in epithelial suspensions and may 
represent a convenient tool during outbreaks.
Serology
The virus neutralization test is considered as the “gold stan-
dard” for detection of antibodies to the SPs of FMDV and is 
a prescribed test for import/export certification of animals/
animal products.44 However, since primary cells and cell 
lines with variable degrees of sensitivities are used, these 
assays are prone to more variability than other serological 
tests. Furthermore, the virus neutralization test is slower 
and requires biocontainment facilities in contrast to other 
serological tests (ie, ELISAs) which use inactivated viruses 
as antigens.
Detection of antibodies against either the SPs or NSPs 
can be determined using ELISAs. As indicated above, vac-
cines consisting of purified preparations of chemically inac-
tivated virus particles induce antibodies almost exclusively 
against the SPs of the virus (at least after a small number of 
 vaccinations) but infection will induce antibodies against the 
NSPs as well. Thus it can be possible to discriminate between 
infected and vaccinated animals based on the detection of 
antibodies to NSPs. A species independent and serotype 
independent blocking ELISA using baculovirus expressed 
FMDV NSPs as antigen is commercially available and widely 
used. Serotype specific ELISAs for the detection of antibod-
ies to the SPs are also described44 and some are commercially 
available or as kits from reference laboratories.
It is clearly important that the design of new vaccines 
against FMDV should consider the importance of being able 
to differentiate between infected and vaccinated animals.
Current vaccines against FMDV  
and novel approaches that could 
elicit a better immunity
As indicated above, current vaccines rely on the production of 
huge quantities of infectious FMDV, generally in large scale 
tissue culture systems; the virus is then chemically inactivated 
and purified (optimally) prior to use, in combination with 
an adjuvant, as a vaccine. Properties of these vaccines have 
been reviewed previously.2,45  Vaccination plays an important 
role in the control of FMD when outbreaks are frequent. For 
example, in Europe during the 1960s and 70s the disease was 
very successfully controlled using a combination of efficient 
veterinary services, movement controls, and vaccination. 
When the disease incidence became very low, vaccination 
was ceased and is no longer permitted in Europe except 
under emergency situations. It is clearly easiest to show the 
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absence of infection if there are no antibodies to FMDV 
within the animal population, however this does leave the 
animals fully susceptible if the virus is introduced. Certain 
countries in Europe (eg, the UK) have never vaccinated 
against FMD but the huge expense and loss of animals dur-
ing the 2001 outbreak in the UK has led to consideration of 
new strategies.
Vaccination has been used in both the Netherlands and 
Japan in the face of outbreaks but in both cases all the vac-
cinated animals were then killed. “Vaccination to live”, as an 
emergency strategy, has not been employed within Europe 
but it is foreseen that if new outbreaks occur in Europe there 
will be a high public/consumer demand for a non-killing 
strategy. In areas of the world where the disease is endemic, 
and no culling of infected animals occurs, vaccination is fre-
quently used around reported outbreaks to reduce the spread 
of the disease. Shortcomings of the current FMD vaccine 
have been outlined above and thus there is significant interest 
in the development of improved vaccines against the disease 
which can assist in the reduction of the disease globally.
The most effective vaccines used to control other viral 
diseases (eg, against smallpox, rinderpest, and PV) have all 
been “live” attenuated viruses but it has not been possible 
to derive safe, effective infectious FMDV strains as vaccine 
candidates. This may partly reflect the diversity of the hosts 
for FMDV and the ability of the virus to change (and thus 
potentially revert to virulence). “Live” attenuated vaccines 
have the property of producing viral antigens within the 
infected cells and short peptides derived from such antigens 
are then displayed on the surface of infected cells in associa-
tion with host MHC proteins, this is particularly important 
for the induction of cytotoxic T-cells. However, the role of 
cytotoxic T-cells in generating protection against FMDV 
is not clear46 but induction of other T-cell responses may 
affect the duration of immunity.47 Inactivated vaccines are 
recognized by antigen presenting cells and principally induce 
a B-cell response but this response is positively influenced by 
the presence of CD4(+) T-cells, since depletion of these cells 
reduces the level and nature of the antibody response.48
In the early days of genetic engineering it was very 
popular to try and express the FMDV VP1 in a variety of 
different forms, in numerous systems, to try and produce a 
non-infectious “subunit” vaccine. However, none of these 
proved very effective in inducing a good protective immune 
response in natural host animals. The unprocessed capsid 
precursor protein P1-2A does share some characteristics with 
the virus in terms of its antigenicity and it is able to bind to the 
integrin receptor (αvβ6) that is used by the intact virus.23,49,50 
However, this precursor protein is not very immunogenic and 
fails to generate a protective immune response.46,49
Hence, more recently, the focus has been on expressing 
“empty capsid particles” (see Figure 2) since these non-infec-
tious particles (lacking the viral genome) have the same anti-
genic and immunogenic properties as whole viruses19,51 while 
having the advantage of not constituting a risk of spreading 
from the production plant. However, achieving the efficient 
expression of FMDV empty capsid particles has not proved 
completely straightforward (see below). In addition, unmodi-
fied empty capsids may suffer from some of the same issues 
as vaccines based on inactivated virus but should at least 
remove the need for virus growth under high containment 
facilities. The production of empty capsid particles does not 
need NSPs (other than 3Cpro) and thus removes the possibility 
of these products inducing an anti-NSP immune response. 
This should improve the ability to discriminate infected from 
vaccinated animals. Furthermore, a good expression system 
may offer the possibility of modifying the FMDV capsid in 
a manner which is not possible when FMD virus viability is 
also required for the production system.
Primary requirements for FMDV  
“empty capsid” production
In principle, the production of FMDV “empty capsids” should 
require the co-expression of the P1-2A capsid precursor 
with the 3Cpro, this can produce the processed products VP0, 
VP3, and VP1 which can self-assemble into particles (Figure 
2). Indeed this was successfully demonstrated many years 
ago.19 The system used at that time involved the use of two 
separate recombinant vaccinia viruses, one expressing the T7 
RNA polymerase and another which contained the FMDV 
P1-2A+3Cpro cDNA cassette downstream of a T7 promoter. 
When cells were co-infected with both recombinant viruses 
then production of FMDV “empty capsids” could be observed. 
However, this system is not suitable for use in animals as 
it is not possible to ensure co-infection of cells by the two 
separate viruses. Constitutive expression of the P1-2A+3Cpro 
from a single recombinant vaccinia virus was not achieved 
since it was not possible to isolate such a recombinant virus; 
it appeared that the expression of this cassette had a negative 
effect on the growth of the virus vector.52
Secondary requirements  
for “empty capsid” production
Picornavirus RNA is produced and functions within the cyto-
plasm of cells, hence the nucleus is a “foreign” environment 
for it. The vaccinia virus expression system described above 
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is very suitable for the expression of picornavirus cDNA 
since all the transcription (to make RNA) occurs within the 
cytoplasm of the cell whereas the host cell  transcription 
machinery is present within the nuclei and host cell RNA 
transcripts are extensively modified (eg, by splicing, capping, 
and polyadenylation) before the mature mRNAs are trans-
ported from the nucleus to the cytoplasm so that translation 
can occur. This means that picornavirus cDNA, and especially 
RNA transcripts derived from it, may be inappropriately 
recognized (eg, for splicing) within the nuclei of cells. It is 
worth noting that the initial system,53 using cloned cDNA, to 
rescue PV used cDNA under the control of an SV40 promoter 
(which is only functional within the nucleus). The infectiv-
ity of this cDNA was very low, a few plaque forming units 
(pfu) were generated per µg of plasmid whereas systems that 
produce RNA transcripts from picornavirus cDNA in vitro 
can achieve .105 pfu/µg of RNA.54 Thus, the transcription 
of picornavirus cDNA from within the nucleus appears to 
be very inefficient at achieving the cytoplasmic expression 
of intact picornavirus RNA and hence expression systems 
which avoid this may be preferable.
The amino terminus of the P1-2A capsid precursor is 
myristoylated (see above). This post-translational modifica-
tion is achieved by a cellular system which is present within 
mammalian and insect cells but lacking in Escherichia coli 
(unless specific steps are taken to achieve this).50 The assem-
bly of the processed FMDV capsid proteins into pentamers 
(12S) and subsequently into empty capsid particles (75-80S) 
is inhibited if myristoylation is blocked;19,50 similar obser-
vations have been reported previously for PV.20,55,56 Thus it 
seems necessary to employ expression systems which permit 
this modification.
Successful expression of “empty capsid” 
components
As indicated above, the expression of P1-2A+3Cpro cas-
settes has been achieved in cells using vaccinia virus based 
vectors19,51,52 and has been optimized by achieving reduced 
levels of the 3Cpro expression relative to the P1-2A.23,24,51,57 
These systems generate empty capsid particles which can 
be detected by sucrose gradient analysis and by electron 
 microscopy. The structure of these particles has been deter-
mined by 3D-reconstructions from electron micrographs23 
and by X-ray crystallography.51 Furthermore, despite some 
of the potential problems described above, it has been pos-
sible to express P1-2A+3Cpro cDNA cassettes using recom-
binant adenoviruses that direct transcription from within the 
nucleus.58,59 No direct evidence for assembly of the expressed 
proteins into empty capsid particles has been reported using 
this system. However, it has been possible to achieve protec-
tion against FMDV challenge in animals using these vectors60 
but high levels of the adenovirus are required which may 
suggest that the expression of the FMDV proteins is relatively 
low, albeit detectable.46 It is noteworthy that adenovirus vec-
tors expressing serotype A (A24) cassettes have proved to be 
more successful than serotype O (O1 Campos) but the basis 
for this difference is not defined.61
The baculovirus expression system also uses transcrip-
tion from within the nucleus but most baculovirus transcripts 
are not spliced and it therefore appears that the potential for 
adverse modification of transcripts derived from FMDV cDNA 
within recombinant baculoviruses is more limited.62 However 
the baculovirus expression system has proved sensitive to the 
activity of the FMDV 3Cpro. Thus it has required introduction of 
both a frameshift signal (to reduce 3Cpro expression level) and 
introduction of an amino acid substitution, to reduce protease 
activity,63 to allow satisfactory expression and processing of 
the P1-2A precursor into empty capsids.51,64 This system has 
permitted the expression of a stabilized form of FMDV empty 
capsids (with a single amino acid change in VP2) which display 
tolerance to heat or low pH treatment and are able to induce 
protection against FMDV challenge.51 A feature of the bacu-
lovirus system is that the virus can be grown in insect larvae 
and generate large amounts of protein.65–67
A recent report has described the co-expression of VP0, 
VP3, and VP1 as His-tagged SUMO (small ubiquitin-like 
modifier) fusion proteins in E. coli.68 After removal of 
the His-SUMO moieties using SUMO protease, apparent 
assembly of the capsid proteins into virus-like particles (ca 
25 nm diameter), that sedimented at 75S, was observed. 
These were able to induce protection in guinea pigs, pigs, 
and cattle against FMDV challenge. Precise details of the 
protein sequences present within these particles are lacking 
and the issue of VP0 myristoylation was not addressed. It is 
therefore unclear how these particles have assembled.
The role of NSPs, as well as other 
elements, for the development  
of more effective vaccines
Recent studies61,69 have demonstrated that inclusion of the 
FMDV 2B coding sequence into the P1-2A+3C cassettes 
expressed from recombinant adenovirus vectors have improved 
the properties of both serotype A and O cDNA  cassettes. 
The analyses indicated that improved T-cell responses were 
obtained but there was no difference in the level of neutral-
izing antibodies generated. A rather different strategy for 
Virus Adaptation and Treatment 2015:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
19
Candidate vaccines to improve control of FMD
enhancing the immune response to FMDV vaccines has been 
described70 in which RNA transcripts, including the IRES, were 
delivered in conjunction with commercial inactivated FMDV 
vaccine and found to enhance the anti-FMDV antibody titers 
in mice. It was suggested that the RNA transcripts acted like 
an adjuvant. The RNA transcripts were found to be potent 
type-I interferon inducers and this may underlie this effect. 
It is well known that interferon has a strong inhibitory effect 
on FMDV replication and studies have shown that expression 
of interferon, from adenovirus vectors, can effectively block 
FMDV replication in swine.71
The precise deletion of the Lb coding region to make a so-
called “leaderless virus” (see Figure 4) from FMDV results in 
a virus which is still viable72–74 but attenuated in cattle.75 The 
loss of Lb results in a decreased ability of the virus to shut 
off host cell protein synthesis; this will allow the synthesis 
of interferon.76 Such viruses can grow well in BHK cells73,74 
and may represent useful tools for the development of safer 
vaccine strains for conventional cell culture production since 
any escape only releases viruses that are non-pathogenic and 
cannot revert to virulence.
There has been significant interest recently in generating 
marked FMDVs which may permit improved DIVA and/
or offer alternative routes for virus purification. Sequences 
for the HA and FLAG epitope tags were inserted into the 
VP1 within the virus capsid without adverse effect on virus 
growth.77 In an alternative strategy, it has been shown that the 
cleavage of the VP1/2A junction (by 3Cpro) is not required 
for virus viability24,78 and the modification of the cleavage 
site can result in the formation of “self-tagged” virus par-
ticles which contain the VP1-2A fusion protein. Thus no 
“foreign” sequences are added to the genome but the pres-
ence of the 2A attached to the VP1 can be readily detected 
(using anti-2A antibodies). The epitope-tagged viruses and 
“self-tagged” viruses offer the possibility of  alternative 
(serotype  independent) purification systems for virus  antigen. 
They should also induce a distinct immune response com-
pared to the native virus which could be used as part of a 
DIVA system. However, use of such “tags” does not allow the 
identification of animals which have been vaccinated and then 
infected. It is important to note that current FMDV vaccines 
do not prevent infection but only disease; indeed vaccinated 
animals can become “carriers” (see above).
Alterations in the immune  
response that are caused  
by infection with FMDV
The major focus of the immune response against FMDV is 
production of antibodies that can recognize and neutralize 
the virus. Such antibodies are generated within 4–7 days of 
infection and their detection within serum is coincident with 
the cessation of viremia within infected animals. Antibodies 
to NSPs are also generated but these tend to appear a little 
later.79 The role of T-cell responses in immunity against 
FMDV is rather poorly understood. Infection of cattle does 
not appear to have an adverse effect on the ability of these 
animals to mount an immune response against FMDV,80 
however a transient loss of circulating T-cells has been 
reported in swine.81
As mentioned above, in about 50% of infected cattle, 
after the acute phase of infection which normally resolves 
within about 14 days, a long-term “carrier” state can occur 
for up to 2–3 years. It occurs despite the presence of neu-
tralizing antibodies in the serum. Since FMDV does not 
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Figure 4 Production of attenuated “Leaderless” FMD viruses.
Notes: Precise deletion of the Lb coding region from the FMDV polyprotein coding region generates a “Leaderless” form of the virus which has been shown to be attenuated 
in cattle. Such viruses can still replicate efficiently in cell culture and may allow the safer production of FMDV vaccines.
Abbreviations: FMDV, foot-and-mouth disease virus; FMD, foot-and-mouth disease.
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survive for very long at 37°C,82 it seems that the virus must 
be replicating within the carrier animal in a site which is 
protected from the host immune response. The site of such 
replication is not precisely established; both the dorsal 
soft palate and germinal centers of lymph nodes have been 
identified as sites of long-term virus maintenance83,84 but 
biopsy samples taken from both of these sites from “car-
rier” cattle that were excreting virus failed to detect the viral 
RNA in most of these tissue samples.85 It seems unlikely 
that cells can tolerate a long-term infection by FMDV, the 
loss of host cell protein synthesis which occurs at very low 
levels of FMDV L protein expression, should be lethal. This 
either suggests that infection of fresh cells is occurring on a 
regular basis, albeit probably involving a small number of 
cells at any one time, or that a mutant form of the L protein 
is expressed by the viruses within carrier animals but there 
is no evidence for this.
The germinal centers of lymph nodes from cattle and buf-
falo that have been infected by FMDV can contain viral RNA 
and protein for extended periods of time but this is believed to 
be in a non-replicating form84,86 and it is not known whether 
such virus can infect other cells. As indicated above, although 
it is generally believed that pigs do not become carriers, 
evidence has been presented that the FMDV RNA and SPs 
can also be detected in porcine lymph nodes for some weeks 
after infection87 but no infectious virus could be recovered 
from these tisssues.11,88
Immune response elements  
that might contribute  
to protection against acute  
and persistent infections
FMDV replication is highly sensitive to type I interferon and, 
as described above, the virus has a mechanism for stopping 
virus-infected cells from producing interferon (and other host 
proteins) by blocking host cell protein synthesis. However, 
within FMDV infected cattle it has been possible to detect 
interferon within the serum of acutely infected cattle.89,90 It 
therefore seemed possible that the interferon detected did 
not originate from FMDV infected cells but potentially from 
other cells that detected some of the viral components. It has 
been reported that bovine plasmacytoid dendritic cells are 
the major source of type I interferon in response to FMDV 
infection.90 However, these cells are believed to interact with 
viruses within immune-complexes and it is not clear whether 
these would be present during the acute phase of infection 
when the interferon response is observed,89 some days before 
anti-FMDV antibodies are detectable in serum.
One process that may contribute towards the ability of 
FMDV-infected cells to be maintained within the host is the 
ability of the 2BC protein (or 2B and 2C together) to block 
the transport of proteins to the cell surface.25,26 This can have 
the effect of blocking virus derived peptides from being 
transported and then displayed on the cell surface and hence 
will render the infected cell apparently “normal” and hence 
not subject to immune surveillance.
Changes in cellular signaling 
pathways triggered by FMDV
When FMDV infects cells it can initiate a variety of intracel-
lular responses. These could be triggered by interaction of the 
virus with the cell-surface exposed integrin receptor, through 
the introduction into cells of highly structured RNA, through 
the shut-off of host cell protein synthesis (which can induce 
apoptosis), and by direct effects of viral proteins on host 
cell systems. The virus can combat such host cell responses 
directly, eg, by inducing cleavage of specific proteins involved 
in such events, or more indirectly (but in a general fashion) by 
blocking host cell macromolecular biosynthesis (transcription 
and translation). Some effects of virus infection appear to be 
a combination of such processes. Interferon induction can be 
blocked by inhibiting host cell transcription and translation 
but there are also reports that the FMDV L protease induces 
cleavage of NF-κB91 while the 3Cpro cleaves the NF-κB essen-
tial modulator (NEMO), a bridging adaptor protein required 
for the activation of both NF-κB and interferon-regulatory 
factor signaling pathways.92
Conclusion
Current vaccines developed to control FMD have significant 
shortcomings. However, when used appropriately and in 
conjunction with other control measures, they can be very 
helpful in controlling and even eradicating the disease on a 
regional basis (as achieved in Europe). However, it is likely 
that improved FMDV vaccines will be required to achieve 
the global eradication of the disease. Different situations 
may require different solutions but it seems likely that the 
production of non-infectious, specifically engineered, “empty 
capsid particles” using a suitable expression system will form 
the basis of such improved vaccines.
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